The translocation t(14;19)(q32;q13) was described as recurrent in B-cell chronic lymphocytic leukemia (CLL) in 1985. The chromosomal rearrangement of the immunoglobulin heavy chain (IGH) gene locus resulted in upregulated expression of a new gene, named BCL3, encoding a protein member of the IkB family. 1 It was then reported that t(14;19) was not entirely specific to CLL, because it was also found in other types of chronic B-cell malignancies (for review, see Soma et al.
2 ). The Groupe Francophone de Cytogénétique Hématologique (GFCH) collected 43 chronic lymphoproliferative disorders with t(14; 19) or variant BCL3-translocations between 1988 and 2007, to analyze to what extent this uncommon abnormality could define a subgroup among B-cell malignancies, and to document the consequences of the rearrangement.
Clinical and biological patients' informations were gathered at diagnosis when available. There were 27 men and 16 women, with a median age of 62 years (range, 39-89 years). Thirty-three of 36 patients (92%) had an absolute lymphocytosis, with a median lymphocyte count of 24 Â 10 9 /l (range, 5.4-514 Â 10 9 /l). Seventeen of 39 patients (44%) had splenomegaly. Of the 25 CLL for whom Binet' stage was available, there were 16 (64%) A stages, five (20%) B, four (16%) C. B/C stages were treated at diagnosis, 10 (62%) A stages required therapy quickly. The median of the time to treatment was 1, 2 months for all stages, 10 months for A stages (range, 0 month-7 years). Six of 20 were dead 3 years after diagnosis (Supplementary Table 1 ).
The cytological, histopathological and immunological review were centralized and performed for 30/43 cases by expert hematologists (PF, H M-B) and hematopathologists (FB, F Gaillard) ( Table 1 and Supplementary Table 1 ). There were 20 CLL/small lymphocytic lymphoma (SLL) (WHO classification), including five 'classical' CLL, one SLL and 14 'atypical' CLL with heterogeneous mixture of cells (prolymphocytes and/or lymphoplasmacytoid cells). Fifteen of 20 cases displayed features of disease progression with an increased number of larger cells (para-immunoblasts) and mitoses, and 1/20 cases was transformed into a large B-cell lymphoma (total: 16/20, 80%), six of 20 were borderline with the diagnosis of marginal zone lymphoma (MZL). The other diagnoses were MZL (six patients), lymphoplasmacytic lymphoma (LPL) (borderline MZL) (one patient), diffuse large B-cell lymphoma (DLBCL) (two patients) and T-cell rich B-cell lymphoma (one patient). Two cases (one DLBCL, one T-cell rich LBCL) could be transformed MZL. Two of six MZL displayed features of disease progression. The other cases which could not be reviewed were classified as 10 CLL/SLL, including four 'classical' CLL and six 'atypical' CLL; two DLBCL; one mantle cell lymphoma. In total, there were 30 CLL/SLL out of 43 cases (70%). Of the 36 patients with the CD5 expression available, 31 (86%) were CD5 þ , including 28/30 (93%) CLL/SLL (six of which being borderline with MZL), 2/5 (40%) MZL and 1 LPL. The Matutes' score (or modified score by Moreau et al.) could be applied for 23 cases. Regarding CLL patients, 14/18 (78%) had a score p3.
Forty-two conventional cytogenetic (CC) analyses were performed, 35 prior treatment, including 27 at diagnosis, and all were reviewed by the GFCH's members (Table 1 ). Only two cases had an isolated translocation: one CLL and one MZL with variant t(2;19). In three cases (5, 12, 33) , the t(14;19) appeared as a secondary change during karyotypic progression. Twentytwo (52%) exhibited complex karyotype (X3 abnormalities), fifteen (36%) unbalanced translocation(s) in addition to t (14;19) . The most frequent chromosomal abnormalities associated with t(14;19) were: trisomy 12 in 22/42 (52%), 6q deletion in 7/42 (17%), 1q rearrangement in 7/42 (17%), trisomy 3/partial trisomy 3q in 6/42 (14%), monosomy 11/11q deletion in 6/42 (14%), monosomy 17/17p deletion in 5/42 (12%), trisomy 18 in 4/42 (10%), monosomy 7/7q deletion in 4/42 (10%), 13q deletion in 4/42 (10%). When trisomy 12 was present, it was the sole additional abnormality in 13/22 cases (59%). Trisomy 12 was confirmed by FISH in 21 patients and detected in one patient (case 13) who lacked conventional cytogenetic analyses. The following losses were detected with commercial probes by FISH: 6q21 in 8/37 analyzed cases (22%), TP53 in 6/35 (17%), 13q14 in 5/38 (13%), ATM in 3/34 (9%) ( Table 2 ). To confirm the presence of BCL3 involvement, FISH using a BCL3 breakapart probe (RP11-876A24 centromeric, RP11-1147O10 telomeric) was applied. A signal split was observed in all 42 examined cases. Juxtaposition of BCL3 to IGH was proven with the IGH probe in 41/42 cases with t(14;19). BCL3 and IGK probes were juxtaposed in the case with t(2;19).
IGHV mutation analysis was performed in 24 cases including 20 CLL, two MZL, one LPL, one LDBCL (Table 1) . Based on a conventional 98% identity cutoff, in 19 cases (79%) including 18 CLL, IGHV sequences showed 99-100% sequence identity to germline VH-genes and were considered as unmutated. In the remaining five cases (21%) including two MZL, one LDBCL and two CLL, the sequence identity ranged from 87.8 to 97.1% indicating somatic hypermutations had occurred. Four cases (17%) expressed the IGHV4-34 gene, all of them having 100% identity with the germline sequence. Six cases (25%) expressed the IGHV4-39 gene, five of which (21%) with the same IGHV4-39/IGHD6-13/IGHJ5 rearrangements exhibiting a highly similar eight aminoacid long HCDR3 junction. These five cases were all CD5 þ , nonmutated, and the frequency of this subset among CLL cases was 25% (5/20) .
To study the consequences of the t(14;19) or t(2;19) on transcription, we measured the expression of BCL3 and five other genes located close to BCL3 locus on 19q13 (Supplementary Figure 1 ). Quantitative RT-PCR revealed a threefold to 18-fold increase of BCL3 expression in t(14;19)-CLL cases compared to the median of CLL controls without t (14;19) . The normalized expression level of BCL3 in the two groups was significantly different (median: 11.5 vs 2.9, P ¼ 0.002) (Figure 1 ). The variations of the expression of the other genes were not statistically different with respect to the controls (Supplementary Figure 2 and data not shown). Interestingly, the two lymphomas (cases 34, 38) expressed higher levels of PVRL2 and lower levels of BCL3, with respect to the other t(14;19) patients. Furthermore, RELB was concomitantly highly expressed in one of these two latter patients (case 38). These variations could merely reflect different transcriptional control in the region.
Although they share features with common CLL, such as age, sex distribution and CD5 expression, particular characteristics of Letters to the Editor (14;19) . According to conventional CLL series and our own data (not shown), trisomy 12q and 6q21 deletion were more frequent than in common CLL (67 vs 13.6-16%, Po10
À11
, and 19 vs 4.6-6%, Po0.02 respectively), while 13q14 deletion was less frequent (14 vs 55-57.4%, Po10 À5 ). 4 Trisomy 12 also was frequent in t(14;19)-CLL in other series, but to our knowledge, the high frequency of del(6q21) and the low frequency of del(13q14) in t(14;19)-CLL are reported for the first time. 2, 5 The vast majority (90%) of the t(14;19)-CLL of the present series expressed unmutated IGHV genes, which is remarkably higher than the 46% reported in the literature for common CLL (Po0.001). 6 Strikingly, two genes (IGHV4-39 and IGHV4-34) accounted for almost half (45%) of the IGH repertoire. Five cases (all CLL) expressed a stereotyped IGHV4-39/IGHD6-13/IGHJ5 receptor, which has been previously described in CLL. However, its frequency in t(14;19)-CLL was much higher than in conventional CLL series (25 vs 0.9-1.2%, Po0.001). Martin-Subero et al. 5 also recently reported in an independent series of ours the same rearrangement in three t(14;19)-CLLs. These findings strongly suggest that these IGHV4-39-expressing CLL cases may recognize similar antigenic structures. In common CLLs, this subset has been found to be associated with specific features such as its occurrence in female patients, an IgGk isotype expression. In our series they differed by a male predominance (4/5) and their IgGl isotype (3/4 with available information). The IGHV4-34 gene is frequently used in CLL (8.1%), mostly in a mutated form (79%). In contrast four (20%) of our t(14;19)-CLL expressed this gene, all being completely unmutated, whereas these represent only 15% of IGHV4-34 expressing common CLL. 6 Finally, as expected, t(14;19) is associated with BCL3 high expression in CLLs. BCL3 high expression is, however, not limited to t(14;19)-CLL nor to B-cell malignancy. Abnormal BCL3 expression was also reported in Hodgkin's disease and peripheral T-cell lymphoma. With respect to t(14;19)-CLL cases, our results confirm previous reports 5 and support an individualization of a CLL subgroup. . 3 In the current study, the median time from diagnosis to initial therapy was 10 months for A stages, 1.3 months for all CLL stages, 2.3 months regarding t(14;19)-CLL cases with trisomy 12, which was very short compared to the median treatment-free intervals for common CLL groups with 17p deletion (9 months), 11q deletion (13 months), 12q trisomy (33 months) and 13q deletion as the sole abnormality (92 months) reported in the literature. 4 Moreover the high percentage of unmutated CLL (90%) and complex karyotype (13/29, 45%), the presence of translocation t(14;19) itself, which are poor prognosis factors, would support the same conclusion. 7, 8 t(14;19) is not restricted to CLL and is associated with heterogeneous B-cell malignancies in previous series. 2, 5 In our series, it is noteworthy that diagnosis was difficult for seven cases between CLL, MZL and LPL, the most frequent diagnosis after CLL being MZL. Common features with t(14;19)-CLL are, however, frequently observed among MZL cases, such as CD5 expression, trisomy 12, leukemic presentation and morphological characteristics of disease progression. In addition, MZL- FISH studies with IGH-CCND1 probes ruled out a cryptic t(11;14)(q13;q32) translocation.
e Unmutated % identity not communicated.
Letters to the Editor associated chromosomal abnormalities such as 7q deletion, trisomy 3 and 18 were rare in our series (Table 2 ).
In conclusion, the two most frequent t(14;19)-associated disorders are CLL (70%) and MZL (14%), and both have atypical features. t(14;19)-CLL deserves to acquire the status of particular aggressive subgroup defined by cell polymorphism and signs of disease progression, CD5 þ immunophenotype and Matutes score p3, trisomy 12 and 6q deletion associated with t(14;19), unmutated IGHV status with an over-representation of the V4-39/D6-13/J5 repertoire, and high BCL3 expression. These observations indicate the deregulation of the NF-kB pathway in mature B-cell malignancies. Considering the already known function of BCL3 and its relation with NF-kB, it could represent a future therapeutic target. Treatment with oncogenic tyrosine kinase inhibitors has led to a dramatic change in the overall survival rates of patients with chronic myeloid leukemia (CML). 1 Dasatinib is an oral tyrosine kinase inhibitor of bcr-abl, Src, c-kit and the platelet-derived growth factor receptor-alpha and -beta (PDGFR-a, PDGFR-b). Like imatinib, it has been shown to be safe and effective in patients with CML. 2 Both drugs are capable of prompting interaction with different enzyme cascades but their mechanism of action and side effects are still under investigation. For example, c-kit, PDGFR-a and PDGFR-b are also important signal transduction modulators in testis organogenesis, Leydig's cell differentiation and recruitment, spermatogenesis and steroidogenesis, whereas Src supports spermatogenesis and fertility by acting as a signal transductor for testosterone action in Sertoli cells. 3, 4 The authors of two recent reports document several cases of gynecomastia in male patients treated with imatinib for CML or gastrointestinal stromal tumor and hypothesize a mechanism by which the drug reduces testosterone production through the block of PDGFR and c-kit in the testis. 5, 6 We describe gynecomastia and its management in a male patient after treatment with dasatinib for CML.
In April 2007, a 70-year-old man was referred to our center for leukocytosis (white blood cells (WBC) 17.7 Â 10 9 /l, hemoglobin (HGB) 13.5 g per 100 ml, platelets (PLT) 230 Â 10 9 /l) and mild splenomegaly. After a bone marrow aspirate, he was diagnosed with CML in the chronic phase. The karyotype 46,XY,t(9;22) (q34;q11) was found in 85% of the metaphases. In May 2007, he started treatment with 400 mg oral imatinib daily. Complete hematologic response was achieved after 24 days of therapy. Immediately before undergoing bcr-abl molecular evaluation, planned at the third month of therapy, the patient developed skin toxicity (Grade 3 Common Toxicity Criteria) with generalized erythema and widespread maculopapular eruption associated with severe pruritus. Imatinib was stopped for 3 weeks with some dermatologic improvement. Only a few days after reintroducing oral imatinib (200 mg daily) in combination with steroids, the patient experienced recrudescence of the skin disorders. Imatinib treatment was then definitively discontinued due to nonhematologic intolerance to the drug.
In September, blood tests showed leukocytosis (WBC 14.8 Â 10 9 /l, HGB 13.7 g per 100 ml, PLT 240 Â 10 9 /l) and cytogenetic evaluation of bone marrow revealed 80% of metaphases harbouring the 46,XY,t(9;22)(q34;q11) translocation. Considering the patient's intolerance to imatinib, treatment was started with oral dasatinib, 100 mg daily. Complete hematologic response was achieved after 21 days of therapy. Two months later, physical examination revealed bilateral gynecomastia, with enlargement of soft and elastic tissue concentric to the nipple area (Figure 1) . Moreover, the patient complained of severe pain in the nipple areas (odynomastia). A mammography showed bilateral fibroglandular enlargement, particularly in the left mammary gland. The full spectrum of steroid and stimulating hormones was evaluated and a retrospective analysis on serum stored before dasatinib therapy was performed ( Table 1 ). The patient had not taken any other medication potentially capable of influencing hormone levels.
At this point, dasatinib was combined with tamoxifen, a selective estrogen-receptor modulator, at an oral dose of 20 mg daily. Within 1 month of treatment, there was significant regression of gynecomastia with decreased nipple pain and tenderness ( Figure 2 ). Four months after starting treatment with dasatinib, the patient was also evaluated for CML: bone marrow analysis showed complete cytogenetic response and undetectable bcr-abl transcript by real-time PCR. 1 This case report leaves us with some open questions: firstly, what mechanisms of dasatinib are involved in gynecomastia? Secondly, why did our patient develop gynecomastia during dasatinib treatment and not when taking imatinib? Thirdly, should we treat CML patients with gynecomastia triggered by tyrosine kinase inhibitors?
Our patient had reduced levels of testosterone and free testosterone besides elevated 17-hydroxyprogesterone (17-OHP). The rise in 17-OHP could be attributable to an accumulation of steroid precursors consequential to impairment of key enzymes of the steroidogenic cascade, such as 17,20 Lyase (Cyp 17) or 17 ketosteroid reductase. 5 By inhibiting c-kit and PDGFR, imatinib is likely to reduce the cytoplasmatic availability of Cyp 17 and testosterone production. 6 Reduced Figure 1 Bilateral gynecomastia, with enlargement of soft and elastic tissue concentric to the nipple area, 2 months after dasatinib treatment
